SynAct Pharma names Thomas Boesen as Chief Operating Officer

Report this content

SynAct Pharma AB (“SynAct”) today announced the appointment of Dr. Thomas Boesen as Chief Operating Officer (COO), effective immediately. His operational role as the new COO will be to drive forward the company’s three trials in clinical development with lead compound AP1189.

Dr. Boesen has more than 20 years’ experience in the biotech and pharma industry. With a PhD in bioorganic chemistry from Copenhagen University, studies at Cambridge University and a MA in technology management from Roskilde and Edinburgh Universities, Dr. Boesen brings significant managerial and scientific strength to the company and will be a critical addition to the SynAct management team to help ensure execution of the company’s portfolio of development projects.

Before joining SynAct, Dr. Boesen worked at Novo Nordisk, and prior to that he was co-founder and COO of the Swiss biotech TXP Pharma. Dr. Boesen was also instrumental in the success of the Danish biotech company Action Pharma, sold for DKK 110mn. USD to Abbvie, and in another successful biotech, Epitherapeutics, sold to Gilead for DKK 444mn in 2015, where he was the co-inventor of the key assets in the deal.

“Bringing on Thomas as COO is a key step for us in helping make sure SynAct and its range of projects successfully progress in clinical development,” said SynAct’s CEO Jeppe Øvlesen,

“I am excited for this opportunity to contribute to the success of SynAct’s unique resolution therapy approach to inflammation, which holds a lot of promise. There is a large medical need and this new approach may be a breakthrough for developing novel medications,” said Dr. Boesen, who has been a shareholder in SynAct Pharma since the IPO, and currently holds 152,946 shares in the company.

The information was submitted, through the agency of the contact person below, for publication on January 26, 2021.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                             Thomas Jonassen
CEO, SynAct Pharma AB                                                            CSO, SynAct Pharma AB
Phone: +45 28 44 75 67                                                              Phone: +45 40 15 66 69
Mail:                                                     Mail:

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: